Cargando…

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium

Delirium occurs very frequently in cancer patients. Insomnia is a symptom of delirium. Lemborexant is a drug that regulates sleep–wake rhythms without causing extrapyramidal symptoms. Based on its ability to improve sleep, lemborexant is expected to have efficacy for insomnia with delirium. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terada, Tatsuto, Hirayama, Takatoshi, Sadahiro, Ryoichi, Wada, Saho, Nakahara, Rika, Matsuoka, Hiromichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2022
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081046/ https://www.ncbi.nlm.nih.gov/pubmed/35099287 http://dx.doi.org/10.1089/jpm.2021.0509

Ejemplares similares

Lemborexant for insomnia
Publicado: (2021)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Data-driven categorization of postoperative delirium symptoms using unsupervised machine learning
por: Sri-iesaranusorn, Panyawut, et al.
Publicado: (2023)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

Prevention of delirium with agitation by yokukansan in older adults after cancer surgery
por: Sadahiro, Ryoichi, et al.
Publicado: (2022)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Can Lemborexant for Insomnia Prevent Delirium in High-Risk Patients with Pancreato-Biliary Disease after Endoscopic Procedures under Deep Sedation?
por: Ogura, Takeshi, et al.
Publicado: (2022)

Efficacy and safety of lemborexant over 12 months in Asian adults with insomnia disorder
por: Dash, Amitabh, et al.
Publicado: (2022)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

Yokukansan for perioperative psychiatric symptoms in cancer patients undergoing high invasive surgery. J-SUPPORT 1605 (ProD Study): study protocol for a randomized controlled trial
por: Wada, Saho, et al.
Publicado: (2019)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Comparison of the effect of lemborexant and other insomnia treatments on driving performance: a systematic review and meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

P096 Subjective ratings of medication strength of lemborexant over 6 months in subjects with moderate or severe insomnia
por: Drake, C, et al.
Publicado: (2021)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Effect of gastric acid‐reducing agents on the pharmacokinetics and efficacy of lemborexant
por: Landry, Ishani, et al.
Publicado: (2020)

P097 Incidence of abnormal dreams and nightmares with lemborexant in adults with insomnia: results from two Phase 3 studies
por: Roth, T, et al.
Publicado: (2021)

Effect of discontinuation of lemborexant following long‐term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial
por: Takaesu, Yoshikazu, et al.
Publicado: (2023)

A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103
por: Sadahiro, Ryoichi, et al.
Publicado: (2023)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial
por: Rosenberg, Russell, et al.
Publicado: (2019)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

Improving the Prevention, Detection, and Management of Delirium in Adult Inpatients; an Interprofessional Consultative Team Pilot Project
por: Monaghan, Caitlin, et al.
Publicado: (2023)

Pilot randomized controlled trial of eHealth cognitive-behavioral therapy for insomnia among Spanish-speaking breast cancer survivors
por: Oswald, Laura B., et al.
Publicado: (2022)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2
por: Kärppä, Mikko, et al.
Publicado: (2020)

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant
por: Khazaie, Habibolah, et al.
Publicado: (2022)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents
por: Ikeda, Shunya, et al.
Publicado: (2022)

What prompts patients to present with delirium?
por: Gibb, Kate, et al.
Publicado: (2021)

FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder
por: Okada, Ippei, et al.
Publicado: (2021)

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: A model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents – CORRIGENDUM
por: Ikeda, Shunya, et al.
Publicado: (2022)

Characteristics of patients who were able to switch from benzodiazepine hypnotics to lemborexant
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Effects of Emotional Stability on Insomnia through Anxiety in Patients with Cataracts
por: Ahn, In-Young, et al.
Publicado: (2019)

A Hospital-Based Online Patients Support Program, Online Adolescent and Young Adult Hiroba, for Adolescent and Young Adult Cancer Patients at a Designated Cancer Center in Japan
por: Hirayama, Takatoshi, et al.
Publicado: (2022)

Entrapment of Binaural Auditory Beats in Subjects with Symptoms of Insomnia
por: Lee, Eunyoung, et al.
Publicado: (2022)

The Usefulness of the Armchair Sign for the Diagnosis of Psychosomatic-Prone Myofascial Pain Syndrome in Patients with Incurable Cancer: A Secondary Analysis of a Prospective Multicenter Observational Clinical Study
por: Hasuo, Hideaki, et al.
Publicado: (2021)

Functional and cognitive outcomes after COVID-19 delirium
por: Mcloughlin, Benjamin C., et al.
Publicado: (2020)

Acceptance and commitment therapy-based behavioral intervention for insomnia: a pilot randomized controlled trial
por: El Rafihi-Ferreira, Renatha, et al.
Publicado: (2020)

Occurrence of delirium is severely underestimated in the ICU during daily care
por: Spronk, Peter E., et al.
Publicado: (2009)

Assessing the Accuracy of International Classification of Diseases (ICD) Coding for Delirium
por: Chuen, Victoria L, et al.
Publicado: (2022)

DEX, Delirium and Dilemma
por: Magoon, Rohan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_55i1t55f69ktlhtm4eaemd0r7p